CRAYON
19.8.2020 06:02:10 CEST | Business Wire | Press release
Crayon, a global leader in digital transformation services, is proud to announce it has entered into a Strategic Collaboration Agreement with Amazon Web Services (AWS). This relationship will help both Crayon and AWS to bring innovation to clients faster, and help them best leverage the transformational power, economics, and agility of the cloud.
Enterprise customers are increasingly relying on AWS to achieve their target business outcomes faster by transitioning to a modern, optimized, cloud-based model. Crayon has a strong track record in migration strategy, implementation, total cost optimization, and cloud economics services. This relationship will help customers have a best-in-class service team to understand what software and infrastructure they have and how to best manage their overall IT estate once they are operating in the cloud.
According to global research and advisory firm Gartner Group, Inc. , spending on cloud infrastructure is projected to grow by nearly 60% in the next two years, while investments in data center systems is projected to decline. This means organizations will have to be smart about their IT investments. Crayon can provide the guidance, tools and expertise to properly manage costs, governance and security in the cloud.
“Collaborating with AWS has been a part of our strategy to build an even stronger commitment to our customers’ success. Alongside AWS we will deliver services to enable our customers to digitally transform, achieve operational efficiencies, and maximize cost optimization to strengthen their performance,” says Crayon CEO Torgrim Takle. “Putting the customer first is in the DNA of Crayon and AWS, and together we will serve more organizations worldwide with world-class solutions.”
Crayon has spent the last several years developing and diversifying its cloud services offerings. Both Crayon and AWS expect this latest collaboration to benefit customers wanting to optimize their overall IT estate utilizing best practices in their cloud adoption framework.
One of those customers who has seen first-hand the power of Crayon and AWS working together is The Future Group, a global company that handles many high-profile projects including those from The Weather Channel and the Super Bowl.
"At The Future Group we have had the great fortune to be able to draw on Crayon's deep knowledge in software development, cloud operations and AWS's wide range of services, to help us build and deliver one of the world's most advanced Mixed Reality solutions for the broadcast industry in record time," said Marcus Brodersen, CEO in The Future Group.
Crayon serves customers in more than 45 countries spanning Europe, the Middle East, Africa, North America, and the Asia-Pacific region.
“Crayon has demonstrated a longstanding commitment of putting customers first and helping them find effective ways to optimize the costs of their IT spend,” said Doug Yeum, Head of Worldwide Channel and Alliances, Amazon Web Services, Inc. “We are delighted to collaborate with Crayon to continue guiding customers through their cloud adoption journey.”
About Crayon:
Crayon helps customers build the commercial and technical foundation for a successful digital transformation journey through a reliable services framework allowing our customers to right-size and optimize their IT estates to unlock technology’s potential and innovation. Headquartered in Oslo, Norway, Crayon has over 1600 employees across approximately 50 locations worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom